Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

917.50 +98.74 (+12.06%)
Delayed Quote Updated: 3:20 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
67 68 Next >
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials ↗
Via Stocktwits
News headline image
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy on the Dip ↗
The market may be overlooking these companies' long-term potential. 
Via The Motley Fool
Topics Government World Trade
News headline image
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon ↗
Via Stocktwits
Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions ↗
Via Stocktwits
News headline image
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors ↗
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
News headline image
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' ↗
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
News headline image
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades' ↗
Cisco reported fourth-quarter revenue of $14.67 billion, and there was a bout of profit taking, Cerity Partners' Jim Lebenthal says. 
Via Benzinga
News headline image
REGENERON PHARMACEUTICALS (NASDAQ:REGN): A Prime Value Investing Candidate with Strong Fundamentals ↗
Discover REGN, a top value investing stock. It boasts strong fundamentals, low P/E ratios, high profitability, and solid financial health, trading below its intrinsic worth. 
Via Chartmill
News headline image
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Where Regeneron Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
News headline image
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top S&P500 movers in Monday's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
News headline image
FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles ↗
Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective corrective actions. 
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts ↗
These companies aren't performing as badly as their stock-market performances this year suggest. 
Via The Motley Fool
News headline image
What's going on in today's session: S&P500 movers ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
These S&P500 stocks are moving in today's session ↗
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was... 
Via StockStory
News headline image
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
News headline image
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Regeneron Pharmaceuticals? ↗
 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.